As of 8 may 2026, as of 8 may 2026, the portfolio of recon (002589) received $3. 16, a decrease of 0. 63 per cent from $3. 18 last week. This week, ricon medicals offered a maximum price of $3. 2 on 6 may. The minimum price was $3. 14 on 7 may. The latest total market value of rhecon medicine is $4,755 million, ranking 24/32 on the market value of the pharmaceutical commercial block and 3665/5200 on the market value of a shares in the two municipalities。
As at 8 may 2026, rhycon's share of the stock was 1. 50. 001 million, or 1. 1 per cent。
In terms of financial flows, the total net outflow of rhecon pharmaceutical resources this week was $21,441 million, the total net outflow of travel funds was $9,863. 7 million and the total net flow of diaspora funds was $31,303. 8 million。
Recon (002589) main medical operations: the company's main business is divided into eight main sectors, namely, pharmaceuticals, vaccines, medical equipment circulation services, third-party medical industry logistics, medical information services, medical logistics services, chinese medicine, hospital operations, medical industry research and development and production, and medical industry finance. According to the recon medical quarterly 2026, the company's corporate income for the first quarter was $1. 707 billion, a decrease of 2. 8 per cent over the same period; net return to the mother's profit of $1,037. 22 million, a decrease of 14. 2 per cent over the same period; deduction of non-net profit of $9. 1455 million, a decrease of 7. 78 per cent over the same period; and a debt rate of 64. 98 per cent, investment earnings of $1,297. 1 million, financial costs of $4,7575,000 and the māori rate of 12. 78 per cent。
The unit has no institutional rating for the last 90 days。
The above elements, which are publicly available information, are generated by ai algorithms (cylindrical code 310104345710301240019) and do not constitute an investment proposal。
